Research Summary: Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CAR-T) therapy that has transformed outcomes for patients with relapsed or refractory multiple myeloma (RRMM), yet head-to-head trials against many commonly used lenalidomide-refractory regimens are not available. This study by...
Read MoreMeeting Highlights: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study. In this study, researchers evaluated the safety and efficacy of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor T-cell (CAR-T) therapy, as standard of care (SOC) for...
Read MoreUnderstanding the role and clinical management of bridging therapy during CAR T-cell therapy for relapsed or refractory multiple myeloma Hwa YL, Doss D, Mangan PA, et al. J Adv Pract Oncol. 2025:1–9. Epub ahead of print. Summary. For patients with relapsed/refractory multiple myeloma (RRMM) who...
Read MoreResearch Summary: For patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM), prior reports have shown median progression-free survival (PFS) of less than six months and median overall survival (OS) of approximately one year. Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell...
Read MoreResearch Summary Chimeric antigen receptor T-cell (CAR-T) therapy is typically administered in the inpatient setting, but accessibility to outpatient administration is expanding. Benefits of outpatient CAR-T administration include broader treatment access, cost savings, reduced healthcare burden, and potentially improved patient quality of life. Ciltacabtagene autoleucel...
Read MoreResearch Summary Advances in T-cell redirecting therapy (TCRT), which includes chimeric antigen receptor T-cell (CAR-T) therapy and bispecific T-cell engagers (TCEs), have favorably altered the treatment landscape of multiple myeloma (MM). Previous recommendations on TCRT use in relapsed/refractory MM (RRMM) were published by the International...
Read More©2026 Oncology Matrix. All Rights Reserved.
